0R0H Stock Chart & Stats
$606.81
$5.89(1.03%)
At close: 4:00 PM EDT
$606.81
$5.89(1.03%)
Day’s Range― - ―
52-Week Range$434.58 - $695.50
Previous CloseN/A
Volume17.00
Average Volume (3M)1.17K
Market Cap
$242.11B
Enterprise Value$228.94B
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$42.55B
Price to Earnings (P/E)35.2
Beta1.09
Next Earnings
Oct 21, 2026EPS Estimate
6.41Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume1,459
30 Day Avg. Volume1,168
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit12.04
Enterprise Value/Ebitda20.94
Forecast
1Y Price Target
$656.06Price Target Upside8.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)25.1
Revenue Forecast (FY)$47.88B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Life-sciences PlatformThe mix of recurring consumables, service contracts, diagnostics, and biopharma activities creates multiple durable revenue streams. Its broad customer base and instrument installed base can support repeat purchasing, workflow integration, and cross-selling across research, clinical, and manufacturing markets.
Strong Free Cash Flow GenerationRobust cash generation supports internal investment, acquisitions, dividends, and buybacks while improving earnings quality. High free-cash-flow conversion gives Thermo Fisher flexibility to fund its broad platform and manage obligations through changing demand conditions.
Raised Growth And Margin OutlookThe raised outlook indicates management expects growth to persist while productivity and operating leverage improve profitability. Organic growth near 4%, acquisition contributions, and planned margin expansion provide a constructive earnings framework over the next several quarters.
Bears Say
Elevated Leverage And Financing CostsHigher leverage reduces financial flexibility and makes interest expense a more persistent claim on earnings and cash flow. It can constrain future acquisitions, buybacks, or investment if operating conditions weaken or financing costs remain elevated.
Profitability Remains Below Prior Peak LevelsAlthough current profitability remains solid, the decline from earlier margin levels suggests that mix and cost pressures have not been fully reversed. Persistently lower margins could limit earnings growth and reduce the benefit of future revenue expansion.
Microbiology Divestiture Creates Ongoing Earnings DragThe planned divestiture removes an established revenue stream and creates a measurable transition-related earnings headwind beyond the transaction close. Management must replace the lost contribution through organic growth, acquisitions, or productivity to sustain overall momentum.
Thermo Fisher News
0R0H FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest share price was $434.58 and its highest was $695.50 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is $242.11B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Oct 21, 2026 which is in 16 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jul 23, 2026. The company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.719 by $0.311.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.28%. See more information on Thermo Fisher dividends here
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 6.41.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of $6.03 in its last earnings report, beating expectations of $5.719. Following the earnings report the stock price went up 9.424%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in GB:0R0H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$656.06 (8.12% Upside)
$656.06 (8.12% Upside)
Blogger Sentiment
Bullish
GB:0R0H Sentiment 64%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $10.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.17%
12-Months-Change
Fundamentals
Return on Equity
0.28%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
0R0H Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all GB:0R0H earnings summaries0R0H Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
0R0H Stock 12 Month Forecast
Average Price Target
$656.06
▲(8.12% Upside)